千金藥業(600479.SH):子公司纈沙坦片獲批上市
格隆匯6月24日丨千金藥業(600479.SH)公吿,近日,公司控股子公司湖南千金湘江藥業股份有限公司(“千金湘江藥業”)收到國家藥品監督管理局核准簽發纈沙坦片的《藥品註冊證書》,該藥品批准上市並視同通過仿製藥質量和療效一致性評價。
纈沙坦片是由瑞士諾華製藥研製的一種血管緊張素II受體阻滯劑,主要用於輕、中度原發性高血壓。該藥首先於2017年獲批進口,是2020年版國家醫保目錄甲類藥品。
纈沙坦片的獲批,為公司的生產經營注入了新動力,對公司的經營業績產生積極影響,同時也為公司其他產品申請上市工作地開展積累了寶貴的經驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.